Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo

Targeted Oncology

Volumn 10, Issue 4, 2015, Pages 501-508

  Young, Natalie R ^a   Soneru, Christian ^a   Liu, Jing ^a,b   Grushko, Tatyana A ^a   Hardeman, Ashley ^a   Olopade, Olufunmilayo I ^a   Baum, Anke ^c   Solca, Flavio ^c   Cohen, Ezra E W ^d  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Afatinib; Cetuximab; Epidermal growth factor receptor; Gefitinib; Squamous cell carcinoma of the head and neck

Indexed keywords

AFATINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; LAPATINIB; NERATINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; EGFR GENE; FEMALE; GENE; GENE AMPLIFICATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IC50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA CELL LINE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; CARCINOMA, SQUAMOUS CELL; DRUG SCREENING; HEAD AND NECK NEOPLASMS; HUMAN; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CETUXIMAB; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; QUINAZOLINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84949093816     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-014-0353-6     Document Type: Article

References (29)

1. Tzahar E, Waterman H, Chen X, Levkowitz G, KarunagaranD LS, Ratzkin BJ, Yarden Y (1996) A hierarchical network or interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276–5287
2. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, Yarden Y (1999) The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A 96:4995–5000
3. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354
4. Grandis JR, Tweardy DJ (1993) Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53:3579–3584
5. Riviere A, Becker J, Loning T (1991) Comparative investigation of c-erbB2/neu expression in head and neck tumors and mammary cancer. Cancer 67:2142–2149
6. Ibrahim SO, Vasstrand EN, Liavaag PG, Johannessen AC, Lillehaug JR (1997) Expression of c-erbB proto-oncogene family member in squamous cell carcinoma of the head and neck. Anticancer Res 17:4539–4546
7. Huang SM, Bock JM, Harari PM (1999) Epidermal growth factor receptor blockage with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59(8):1935–1940
8. Bonner JA, Harari PM, Girald J, Azarnia N, Shin D, Cohen R, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for Squamous-Cell Carcinoma of the Head and Neck. NEJM 354:567–578. doi:10.1016/S1470-2045(09)70311-0
9. Burtness B, Goldwasser MA, Flood W et al (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646–8654
10. Baselga J, Trigo JM, Bourhis J et al (2005) Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23:5568–5577
11. Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. NEJM 359:1116–1127
12. Wakeling AE, Guy SP, Woodburn JR et al (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749–5754
13. Magne N, Fischel JL, Dubreuil A et al (2002) Influence of epidermal growth factor receptor (EGFR), p53, and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (Iressa). Br J Cancer 86:1518–1523
14. Cohen EE, Rosen F, Stadler WM et al (2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980–1987
15. Pollack VA, Savage DM, Baker DA et al (1999) Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-258,774: dynamics of receptor inhibition in situe and antitumor effects in athymic mice. J Pharmacol Exp Ther 291:739–748
16. Soulieres D, Senzer N, Vokes E, Hidalgo M, Agarwala S, Siu L (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77–85
17. Solca F, Dahl G, Zoephel A, Bader G, Sanerson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. JPET 343(2):342–350. doi:10.1124/jpet.112.197756
18. Khelwatty SA, Essapen S, Seddon AM, Modjtahedi H (2011) Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. Int J Oncol 39(2):483–491. doi:10.3892/ijo.2011.1054
19. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34):4702–4711. doi:10.1038/onc.2008.109
20. Shimamura T, Gewulich H, Solca F, Wong K (2007) Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2 in human NSCLC xenografts and in a transgenic mouse lung-cancer model. J Thorac Oncol 2(8):S380. doi:10.1097/01.JTO.0000283232.53465.68
21. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R (2010) Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 28:3965–3972. doi:10.1200/JCO.2009.26.7278
22. Murakami H, Tamura T, Takahashi T, Nokihara H, Naito T, Nakamura Y, Nishio K, Seki Y, Sarashina A, Shahidi M, Yamamoto N (2012) Phase I study of continuous afatinib (BIBW2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother Pharmacol 69:891–899. doi:10.1007/s00280-011-1738-1
23. Schutze C, Dorfler A, Eicheler W, Zips D, Hering S, Solca F, Baumann M, Krause M (2006) Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther Onkol 182:256–264. doi:10.1007/s00066-007-1696-z
24. Liu J, Kuo WL, Seiwert TY, Lingen M, Ciaccio MF, Jones RB, Rosner MR, Cohen EE (2011) Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin. Head Neck 33:1774–1782. doi:10.1002/hed.21701
25. Liu W, Wu X, Zhang W, Montenegro RC, Fackenthal DL, Spitz JA, Huff LM, Innocenti F, Das S, Cook EH Jr, Cox NJ, Bates SE, Ratain MJ (2007) Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res 13:6788–6795
26. Young NR, Liu J, Pierce C, Wei T-F, Grushko T, Olopade OI, Liu W, Shen C, Seiwert TY, Cohen EEW (2013) Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol 7:359–368. doi:10.1016/j.molonc.2012.11.001
27. Zhang L, Castanaro C, Luan B, Yang K, Fan L, Fairhurst JL, Rafique A, Potocky TB, Shan J, Delfino FJ, Shi E, Huang T, Martin JH, Chen G, Macdonald D, Rudge JS, Thurston G, Daly C (2014) ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models. Mol Cancer Ther 13(5):1345–1355
28. Seiwert TY, Fayette J, Cupissol D, Del Campo JM, Clement PM, Hitt R, Degardin M, Zhang W, Blackman A, Ehrnrooth E, Cohen EE (2014) A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 25(9):1813–1820
29. De Grève J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J, Everaert H, Umelo I, In't Veld P, Schallier D (2012) Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 76:123–127. doi:10.1016/j.lungcan.2012.01.008